BMJ Paediatrics Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
GENERAL COMMENTS
This is a very important study aimed to characterize pharmacotherapy for children with HF with the focus to describe how ACE-I are prescribed. This is the revised version which I find very well written.
I would add more description of the characteristics of physicians who did not fill the survey additional to figure 1 , what countries are they, ages, senior doctors or fellows etc. and in the discussion to discuss if and how the 50% of response might bias (if at all) the results.
I saw the that pharmacotherapy with ACE-I and renal failure was addressed. I was wondering why hyperkalemia in the children treated with ACE-I was not addressed.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1:
1.
Question 1: -Did you consider the possibility to identify pediatric cardiologists also through a bibliographic search (e.g. searching for centers/physicians mainly involved in research activities)?
Thank you for posing this question. Yes, we also considered this possibility. However, since our aim was getting a picture of what was actually happening across Europe in everyday clinical practice, we considered focusing in the physicians that are mainly involved in research would have been less representative of the actual situation and could have compromised in a larger extent the generalisability of our study results. Clinicians involved in research, have usually a specific profile. It is reasonable to think they are much more likely to be aware of the evidence available and more willing to integrate this knowledge into their routines and practice evidence-based medicine.
2.
Question 2: -40 out of 100 participant hospitals were based in 3 countries (Germany, Spain and France). Maybe results can be partly influenced by this "cluster" (e.g. choice of ACE-I; starting and manteinance dose). I think it could be interesting (not necessarily for this paper) to evaluate what is the degree of concordance concerning drugs and dosage, stop/withdrawal criteria between and within the above 3 countries.
Thank you for pointing this out. I think you made a very interesting appreciation. Germany, Spain and France are among the 7 most populated countries in Europe and this is consistent with the fact that it was possible to identify a large number of physicians in those countries. Physicians working in those countries were addressed in their own languages, which might have also affected in a positive way the response rate. No, we did not evaluate the concordance of drugs or dosages/withdrawal criteria within those three countries. This might be a future research question.
3.
Question 3: I think it could be helpful for readers to have a list of responders (centers/physicians) Since the main centre in charge of this study is in Düsseldorf, it had to be complied with the strict German Data Protection Law. The Data Protection Officer at our institution highly recommended us not to make any "personal data" open, this means no physician name and no hospital name. This would have required getting a signed informed consent from each of the participating physicians.
This would have complicated the procedure to participate in the survey significantly and was likely to have a negative impact in the response rate. This information, even though interesting, was not actually crucial to interpret the findings. Therefore, the decision was made to gain electronic informed consent via web-survey platform EvaSys®. Even though we recorded hospital name, in order to be sure that all answers were coming from physicians working in different centres, participants were guaranteed that none of their personal data were going to be made open to the public.
4.
Question 4: -page 10: Results concerning ACE-I formulations are not very clear for me. All the responders experienced the situation "adults' formulation is not suitable", but it seems to me that in some EU countries suitable formulations of captopril and enalapril are available. Maybe, it could be helpful for readers to have a brief paragraph summarizing the licensing status and liquid formulation availability of captopril/enalapril in Europe (or at least in the most represented countries) Thank you for pointing this out. Even though we have tried our best to get the exact information of the licensing status of ACE-I in children in Europe, we haven't been able to find solid information about this. To our understanding, none of these drugs is authorised at the moment for the indication heart failure in children in any European country. The British National Formulary for children (2018) states that "ACE-I are not licensed for children" and ACE-I have been recognised among the drugs to be prioritised in paediatric heart failure research by the EMA. As far as we are aware, in the UK a liquid formulation of captopril named NoyadaR is commercialised. However, even though they give some paediatric dosing recommendations in the summary of product characteristics (SPC), when referring to "paediatric population" they include the same sentence as other captopril formulations commercialised "The efficacy and safety of captopril have not been fully established" and there is no specific sentence like "captopril is licensed in paediatrics". It is true, that not having addressed in the relevant questions the fact that this liquid formulation might be in use in some European countries, represents a study limitation. However, in this regard it is worth mentioning that participants had the opportunity of selecting answer option "other" and entering comments that they considered relevant to the question in a free text field. Only one out of the 100 participating physicians mentioned they were using an adult licensed liquid formulation. We will try to briefly address this in the manuscript.
5.
Question 5: -page 10: the sections "Drug regimens for the management..." are a little bit difficult to read (a lot of percentages). I would like to suggest to report in table 2 also the sum of responders using a 2, 3, 4 etc drug regimen. I'm not familiar with the treatment of HF, but I'm a little bit concerned that 1 out of 3 responders use an initial treatment regimen with 4 or more drug classes. Is it rational?
Thank you for this clarification request. The information had already been included at the bottom of the table: "Most of the participants start with 2 (20%), 3 (41%) or 4 (24%) drugs in combination." Thirty-four percent of the participants reported starting with 4 or more drugs in combination. In this regard, we have pointed out in the discussion section it is remarkable that "a large percentage of the participants have a criterion on aldosterone antagonists use that differs from published recommendations, as 65% include them as starting therapy". This seems to be a significant deviation form conditions of use that current adult data support (no systematic paediatric data have been published).
With regard to your comment "the sections "Drug regimens for the management..." are a little bit difficult to read (a lot of percentages)". Thank you for pointing this out, I have worked to reduce the percentages I give in this section, Reviewer 2:
Question 1: I would add more description of the characteristics of physicians who did not fill the survey additional to figure 1 , what countries are they, ages, senior doctors or fellows etc. and in the discussion to discuss if and how the 50% of response might bias (if at all) the results.
Thank you for your comment. The countries where the centres of the physicians that were invited but did not participate, are already included in figure 1. I see your point, the information regarding their work experience or specific position, may had been interesting. Unfortunately, this information was often not available in the sources we used to identify physicians contact data.
With regard to the study response rate, since there are no registries of physicians or centres dedicated to paediatric cardiology across Europe, we were not able to invite a statistically representative sample and therefore, we did not aim to extrapolate our results beyond the population of participating physicians. For this reason, in this particular survey the response rate is an additional data, but does not bias or affect the meaning of the overall results in any negative way.
2.
Question 2: I saw the that pharmacotherapy with ACE-I and renal failure was addressed. I was wondering why hyperkalemia in the children treated with ACE-I was not addressed.
Thank you for pointing this out. The questionnaire length and the time participants need to complete it has proven one of the factors that can negatively affect the participation rate in survey studies. Therefore, unfortunately, it was necessary to leave out topics that might have been relevant and also to address complicated issues in a simplified manner. The toxicity of ACE-I was a particularly challenging topic to address, since the approach used may change depending on patient age, comorbidities, underlying heart disease and concomitant medication. According to literature, hyperkalemia seemed to be less frequent and with less severe consequences than hypotension and renal impairment, (van der Meulen M, Dalinghaus M, Burch M, et al. Question 1: How safe are ACE inhibitors for heart failure in children? Arch Dis Child 2018;103:106-9. doi:10.1136/archdischild-2017-312774) and to be strongly linked with practices regarding diuretics used concomitantly. Therefore, the decision was made to dedicate 4 questions/sub-questions to hypotension and renal impairment and to not address the topic of hyperkalemia.
Requests of reviewers/editors to be reflected in main document: Request 1.
: Results concerning ACE-I formulations are not very clear for me. All the responders experienced the situation "adults' formulation is not suitable", but it seems to me that in some EU countries suitable formulations of captopril and enalapril are available. Maybe, it could be helpful for readers to have a brief paragraph summarizing the licensing status and liquid formulation availability of captopril/enalapril in Europe (or at least in the most represented countries) Status: Done 2.
-page 10: the sections "Drug regimens for the management..." are a little bit difficult to read (a lot of percentages).
Status: Done (also footnote in table 2 has been added with % of participants that use a starting drug combination >=4 drugs)
